Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Epilepsy surgery education and practice around the globe: An ILAE taskforce report
Enslin, Nico , Muh, Carrie R. , Olivera, Tatiana von Hertwig Fernandes de, Alotaibi, Faisal , Ali, Rushna , Dorfer, Christian , Englot, Dario J. , Epilepsy, Epilepsy Surgery Education Taskforce of the International League Against, Nico Enslin, Johannes M , Ali, Rushna P, Dorfer, Christian , Cukiert, Arthur , Englot, Dario J , Muh, Carrie R , Wang, Xiongfei , McKhann, Guy M. , Damisah, Eyiyemisi C. , Rydenhag, Bertil , Epilepsy, Epilepsy Surgery Education Taskforce of the International League Against

Mayo Clinic

Epilepsia | December 5, 2024 | Volume: 66 | Issue: 2 | Pages: 319-327

10.1111/epi.18199 | PMID 39636690 Get It

Abstract Up to 80% of the world's population with epilepsy lives in low and middle‐income countries. Around one‐third of these patients will have drug‐resistant epilepsy, for which epilepsy surgery is an option. Unfortunately, many of these regions, as well as some more developed nations, lack sufficient epilepsy surgery units and trained neurosurgeons. With this in mind, the International League Against Epilepsy (ILAE) formed the Epilepsy Surgery Education Taskforce to address the shortage of further educational opportunities for surgeons and neurologists and to promote the creation of more epilepsy surgery units around the world. In this article, we publish our findings from a web‐based international survey, in which we investigated the global distribution and experience of neurosurgeons who perform epilepsy surgery, their educational paths, and opinions on the further need for epilepsy surgery education, as well as the resources available to them. We report a detailed analysis of the 202 survey replies received from 35 different countries across six continents. The lack of adequate numbers of epilepsy surgery units in the Southern Hemisphere is notable, and the aim of this task force with other ILAE committees, is to improve access to epilepsy surgery for patients and to enhance training for their health care providers.
Single-cell multiomics reveal divergent effects of DNMT3A- and TET2- mutant clonal hematopoiesis in inflammatory response
Ismail, Wazim Mohammed , Binder, Moritz , Kim, Minsuk , Geyer, Susan M. , Mazzone, Amelia , Finke, Christy M. , Mangaonkar, Abhishek A. , Lee, Jeong‐Heon , Kim, Kwan‐Hyun , Simon, Vernadette, Rohakthar, Fariborz Rakhshan, Munankarmy, Amik , Byeon, Seul Kee , Schwager, Susan M., Harington, Jonathan J., Snyder, Melissa R. , Wieben, Eric D. , Gaspar‐Maia, Alexandre , Patnaik, Mrinal M. , Mohammed Ismail, Wazim , Fernandez, Jenna A., Binder, Moritz , Kim, Minsuk , Mazzone, Amelia , Lee, Jeong-Heon , Wang, Liguo , Kim, Kwan Hyun , Simon, Vernadette A, Rakhshan Rohakthar, Fariborz, Munankarmy, Amik , Byeon, Seul Kee , Harrington, Jonathan J. , Robertson, Keith D , Pandey, Akhilesh , Gaspar-Maia, Alexandre , Patnaik, Mrinal , Fernandez, Jenna , Lasho, Terra L. , Wang, Liguo , Robertson, Keith D. , Pandey, Akhilesh , Chia, Nicholas

Mayo Clinic

Blood Advances | December 4, 2024 | Volume: 9 | Issue: 2 | Pages: 402-416

10.1182/bloodadvances.2024014467 | PMID 39631069 Get It

Abstract DNMT3A and TET2 are epigenetic regulator genes commonly mutated in age-related clonal hematopoiesis (CH). Despite having opposed epigenetic functions, these mutations are associated with increased all-cause mortality and a low risk for progression to hematologic neoplasms. Although individual impacts on the epigenome have been described using different model systems, the phenotypic complexity in humans remains to be elucidated. Here, we make use of a natural inflammatory response occurring during coronavirus disease 2019 (COVID-19), to understand the association of these mutations with inflammatory morbidity (acute respiratory distress syndrome [ARDS]) and mortality. We demonstrate the age-independent, negative impact of DNMT3A mutant (DNMT3Amt) CH on COVID-19–related ARDS and mortality. Using single-cell proteogenomics we show that DNMT3A mutations involve myeloid and lymphoid lineage cells. Using single-cell multiomics sequencing, we identify cell-specific gene expression changes associated with DNMT3A mutations, along with significant epigenomic deregulation affecting enhancer accessibility, resulting in overexpression of interleukin-32 (IL-32), a proinflammatory cytokine that can result in inflammasome activation in monocytes and macrophages. Finally, we show with single-cell resolution that the loss of function of DNMT3A is directly associated with increased chromatin accessibility in mutant cells. Hence, we demonstrate the negative prognostic impact of DNMT3Amt CH on COVID-19–related ARDS and mortality. DNMT3Amt CH in the context of COVID-19, was associated with inflammatory transcriptional priming, resulting in overexpression of IL32. This overexpression was secondary to increased chromatic accessibility, specific to DNMT3Amt CH cells. DNMT3Amt CH can thus serve as a potential biomarker for adverse outcomes in COVID-19.
SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation
Frantz, Robert P. , Desai, Shashank , Ewald, Gregory A. , Franco, Verónica , Hage, A., LaRue, Shane , Mathier, Michael A., Mandras, Stacy A. , Park, Myung H., Wang, I‐Wen , Zolty, Ronald , Rendon, G. Gomez, Rocco, Mark A., Selej, Mona , Zhao, Carol, Schilling, Joel D , Frantz, Robert P , Horn, Evelyn M. , Ravichandran, Ashwin Kumar , Rame, J. Eduardo

Mayo Clinic

Pulmonary Circulation | December 4, 2024 | Volume: 14 | Issue: 4 | Pages: No page available

10.1002/pul2.12446 | PMID 39635465 Get It

AbstractMacitentan is a dual endothelin receptor antagonist (ERA) approved for treating pulmonary arterial hypertension (PAH). SOPRANO evaluated the efficacy and safety of macitentan versus placebo in pulmonary hypertension (PH) patients after left ventricular assist device (LVAD) implantation. SOPRANO was a phase 2, multicenter, double‐blind, randomized, placebo‐controlled, parallel‐group study. Patients with an LVAD implanted within the prior 90 days who had persistent PH (i.e., mean pulmonary arterial pressure ≥25 mmHg, pulmonary artery wedge pressure [PAWP] ≤18 mmHg, and pulmonary vascular resistance [PVR] >3 Wood units [WU]) were randomized (1:1) to macitentan 10 mg or placebo once daily for 12 weeks. The primary endpoint was change in PVR. Secondary endpoints included change in right‐heart catheterization hemodynamic variables, N‐terminal prohormone of brain natriuretic peptide levels, World Health Organization functional class, and safety/tolerability. Fifty‐seven patients were randomized to macitentan (n = 28) or placebo (n = 29). A statistically significant reduction in PVR from baseline to Week 12 was observed with macitentan versus placebo (placebo‐corrected geometric mean ratio, 0.74; 95% confidence interval, 0.58–0.94; p = .0158). No statistically significant differences were observed in secondary endpoints. In a post‐hoc analysis, 66.7% of patients receiving macitentan achieved PVR <3 WU versus 40.0% receiving placebo (p = .0383). Macitentan was generally well tolerated; adverse events were consistent with those in previous PAH studies with macitentan. In conclusion, macitentan showed promising tolerability and significantly reduced PVR in PH patients with persistently elevated PVR after LVAD implantation. ClinicalTrials. gov identifier: NCT02554903.
GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β ‐Klotho‐Mediated Ferroptosis Inhibition
Tian, Shasha , Zhou, Saijun , Wu, Weixi, Lin, Yao , Wang, Tongdan, Sun, Haizhen, Aniwan, Ashanjiang, Li, Yaru , Wang, C. D., Yu, Pei , Zhao, Yanjun , Zhao, Yanjun , Wu, Weixi, Li, Yaru, Li, Xiaogang

Mayo Clinic

Advanced Science | December 4, 2024 | Volume: 12 | Issue: 4 | Pages: No page available

10.1002/advs.202409781 | PMID 39630101 Get It

Abstract Semaglutide (Smg), a GLP‐1 receptor agonist (GLP‐1RA), shows renal protective effects in patients with diabetic kidney disease (DKD). However, the exact underlying mechanism remains elusive. This study employs transcriptome sequencing and identifies β ‐Klotho (KLB) as the critical target responsible for the role of Smg in kidney protection. Smg treatment alleviates diabetic kidney injury by inhibiting ferroptosis in patients, animal models, and HK‐2 cells. Notably, Smg treatment significantly increases the mRNA expression of KLB through the activation of the cyclic adenosine monophosphate (cAMP) signaling pathway, specifically through the phosphorylation of protein kinase A (PKA) and cAMP‐response element‐binding protein (CREB). Subsequently, the adenosine monophosphate‐activated protein kinase (AMPK) signaling pathway is activated, reprograming the key metabolic processes of ferroptosis such as iron metabolism, fatty acid synthesis, and the antioxidant response against lipid peroxidation. Suppression of ferroptosis by Smg further attenuates renal inflammation and fibrosis. This work highlights the potential of GLP‐1RAs and KLB targeting as promising therapeutic approaches for DKD management.
3D printable biopolymers as pelvic floor scaffolds
Chambers, Lindsay B. , Zhu, Yuxiang , Yu, Churan , Crutchfield, Natalie , Hou, Jixin , Liu, Yang , Sobczak, M. Taylor , Theobald, Taylor G. , Sun, Xiao , Stoll, Carly R. , Pulido, Tiffany V., Yi, Johnny , Cornella, Jeffrey L. , McIlwee, Heather, Handa, Hitesh , Song, Kenan , Song, Kenan , Zhu, Yuxiang , Liang, Liang , Wang, Xianqiao , Liu, Yang , Sun, Xiao, Brisbois, Elizabeth J. , Lancaster, Jessica N.

Mayo Clinic

Polymer Chemistry | December 3, 2024 | Volume: 16 | Issue: 3 | Pages: 345-355

10.1039/d4py01103a Get It

Our polyvinyl alcohol feedstock was prepared through carbic anhydride functionalization, UV curing during direct ink writing, and base treatment. The scaffold exhibited mechanical properties similar to pelvic floor tissue.
Longitudinal Study of Patients with Connective Tissue Disease–Interstitial Lung Disease and Response to Mycophenolate Mofetil and Rituximab
Li, Yan , Mumtaz, Sehreen , Baig, Hassan , Mira‐Avendano, Isabel , Wang, Benjamin , Rojas, Carlos A. , Stowell, Justin T. , Lesser, Elizabeth R. , Borkar, Shalmali R. , Majithia, Vikas , Abril, Andy , Baig, Hassan Z , Majithia, Vikas , Mumtaz, Sehreen

Mayo Clinic

Diagnostics | December 2, 2024 | Volume: 14 | Issue: 23 | Pages: 2702

10.3390/diagnostics14232702 | PMID 39682611 Get It

Background/Objective: To investigate the effect of mycophenolate mofetil (MMF) and rituximab (RTX) on pulmonary function test (PFT) results in a mixed cohort of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), longitudinally followed up for 1 year in a single academic center. Methods: Patients with CTD-ILD were identified in electronic medical records from 1 January 2009 to 30 April 2019. Prescribed MMF and RTX doses, dosage changes, and therapy plans were analyzed individually with improvement in PFT outcomes determined using multivariable linear regression models during 12-month follow-up. Results: Forty-seven patients with CTD-ILD, treated with MMF, RTX, or both, were included. Patients on combined MMF and RTX had worse PFT outcomes at baseline compared with patients on monotherapy. Substantial improvement was observed among all PFT outcomes from baseline to 12 months, regardless of medication dosage or therapy plans. The diffusing capacity of the lungs for carbon monoxide (DLCO) worsened by an average of 7.21 mL/(min*mmHg) (95% CI, 4.08–10.33; p < 0.001) among patients on RTX compared to combined therapy. Patients on higher doses of MMF at baseline experienced an average increase of 0.93 (95% CI, 0.04–1.82) units in DLCO from baseline to 6 months (p = 0.04) and a 2.79% (95% CI, 0.61–4.97%) increase in DLCO from 6 to 12 months (p = 0.02) within patients on concurrent RTX at 6-month follow-up. Conclusions: The treatment of CTD-ILD with MMF and/or RTX was associated with overall improvement in PFT outcomes. Combined therapy resulted in significant improvements in DLCO compared with monotherapy. Higher doses of MMF also provided greater improvements in DLCO.
Accuracy of Fecal Polymerase Chain Reaction Testing in Clarithromycin-Resistant Helicobacter Pylori: A Systematic Review and Meta-Analysis
Qady, Ahmed Al , Salih, Mohamed, Ali, Marriam, Menakuru, Sasmith, Nayar, Kapil Dev, Wang, Zhen , Bi, Yan , Al Qady, Ahmed , Aldhaleei, Wafa, Harris, Dana, Aldhaleei, Wafa Ali , Nayar, Kapil Dev, Stancampiano, Fernando F. , Harris, Dana M.

Mayo Clinic

Clinical and Translational Gastroenterology | December 2, 2024 | Volume: 16 | Issue: 2 | Pages: e00792

10.14309/ctg.0000000000000792 | PMID 39620581 Get It

INTRODUCTION: The increasing prevalence of clarithromycin (CLA)-resistant Helicobacter pylori (H. pylori) strains poses a significant challenge in the management of H. pylori infections. This systematic review and meta-analysis investigates the diagnostic accuracy of polymerase chain reaction (PCR) in identifying CLA-resistant H. pylori strains in stool. METHODS: A comprehensive literature search was conducted using PubMed, Embase, and Cochrane databases from database inception to April 30, 2023. Eligible studies evaluated the effectiveness of PCR stool tests in detecting CLA-resistant H. pylori strains in adults (>18-year-old). Studies of pediatric populations, alternative methods to PCR or stool samples, and reference tests other than gastric biopsy were excluded. The bivariate random-effects model was used to pool diagnostic accuracy from the included studies. RESULTS: The analysis of 11 prospective diagnostic studies with a total of 866 patients showed a pooled sensitivity of 0.97 (95% CI: 0.9–0.99) and a pooled specificity of 0.98 (95% CI: 0.81–1.00). Subgroup analysis based on the used technique demonstrated consistent findings without notable variations. The diagnostic odds ratio was calculated at 1843.92 (95% CI: 134.28–25,321.3). The positive likelihood ratio was determined as 51.02 (95% CI: 4.61–564.5), while the negative likelihood ratio was found to be 0.03 (95% CI: 0.01–0.1). DISCUSSION: PCR testing for clarithromycin-resistant H. pylori was highly sensitive and specific across studies with proven reliability in clinical practice, particularly in outpatient settings. Their implementation offers cost-effectiveness and the potential for tailored treatment strategies, holding promise for improved patient outcomes.
Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
Bock, Allison M. , Wenzl, Kerstin , Stokes, Matthew E. , Hopper, Melissa A. , Dropik, Abigail R. , Sarangi, Vivek, Ortiz, Maria, Huang, Chuican , King, Rebecca L., Ansell, Stephen M., Gandhi, Anita K. , Nowakowski, Grzegorz S. , Novak, Anne J. , Hopper, Melissa A , Dropik, Abigail R , Wang, Yucai , Witzig, T.E. , Novak, Joseph P. , Krull, Jordan E. , Stong, Nicholas , Maurer, Matthew J. , Farooq, Umar , Wang, Yucai , Witzig, Thomas E. , Ansell, Stephen M. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Hematological Oncology | November 29, 2024 | Volume: 43 | Issue: 1 | Pages: No page available

10.1002/hon.70006 | PMID 39612356 Get It

ABSTRACTDiffuse large B‐cell lymphoma (DLBCL) patients that fail to achieve a complete metabolic response with frontline immunochemotherapy have a poor prognosis. Genomic profiling has led to a broader understanding of the molecular drivers in DLBCL, but it is unknown how well current classifiers identify patients that will experience primary treatment resistance (PTR). Using whole exome and RNA sequencing data from newly diagnosed DLBCL patients, we evaluated the genomic landscape of PTR and compared it to that of non‐PTR DLBCL. We found a significant increase in the frequency of TP53 (34% vs. 15%, p = 0.005) and ARID1A mutations (21% vs. 7%, p = 0.007) in PTR cases, with pathway analysis further demonstrating a downregulation of TP53 and an increase in chromatin modifying pathways. These results suggest that TP53 and ARID1A may be key mediators of PTR and important pathways contributing to the poor outcomes. We found that the current molecular classifiers were unable to identify PTR cases at diagnosis. However, our newly identified high‐risk signature identified 46% of PTR cases at diagnosis. Overall, these results contribute to our understanding of the genomic landscape of patients with primary treatment resistance.
Effects of electric fields on the release and content of extracellular vesicles
Wang, Hai‐Long , Wang, Hai-Long , Wang, Yihua , Worrell, Gregory A.

Mayo Clinic

Journal of Extracellular Biology | November 29, 2024 | Volume: 3 | Issue: 11 | Pages: No page available

10.1002/jex2.70018 | PMID 39619686 Get It

Abstract Extracellular vesicles (EVs) are small membrane‐bound structures that originate from various cell types and carry molecular cargos to influence the behaviour of recipient cells. The use of EVs as biomarkers for diagnosis and as delivery vehicles for treatment in a wide range of human disease is a rapidly growing field in research and clinical practice. We hypothesized that electric fields (EFs) could influence the release and content of EVs. To examine this hypothesis, we developed a specialized bioreactor enabling cells to thrive in a three‐dimensional setting, replicating in‐vivo conditions amidst programmable EF environments. We established a three‐step EV purification protocol to achieve high‐density production of EVs. We also performed mass spectrometry‐based proteomics analysis on EV‐carrying proteins and used high‐resolution nanoparticle flowcytometry for single‐vesicle analysis. Findings from this report suggest that electrical stimulation, employing physiologically relevant amplitudes typical in therapeutic deep brain stimulation, influences the release of EVs and their cargo content in a frequency‐dependent fashion. This conclusion could carry significant implications for both fundamental biological understanding and medical advancements. First, it raises an intriguing question about how the endogenous electrical activity of neuronal and other cellular assemblies influence the production and composition of EVs. Second, it reveals a novel underlying mechanism of how therapeutic electrical stimulations can modulate EVs and treat human brain disorders. Third, it provides a novel approach to utilize electrical stimulation for generating desired EV cargos in a programmable setting.
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium
Day, Jonathan R , Koff, Jean L. , Wang, Yucai , Lossos, Izidore S. , Nastoupil, Loretta J. , Strouse, Christopher , Chihara, Dai , Martin, Peter , Leonard, John P. , Cohen, Jonathon B. , Ruan, Jia , Friedberg, Jonathan W. , Flowers, Christopher R. , Koff, Jean L , Wang, Yucai , Lossos, Izidore S , Nastoupil, Loretta J , Chihara, Dai , Cohen, Jonathon B , Kahl, Brad S , Burack, W Richard , Cerhan, James R , Link, Brian K , Maurer, Matthew , Casulo, Carla , Strouse, Christopher S , Larson, Melissa C. , Durani, Urshila , Habermann, Thomas M. , Martin, Peter, Kahl, Brad S. , Burack, Richard , Cerhan, James R. , Link, Brian K. , Maurer, Matthew J. , Casulo, Carla

Mayo Clinic

Blood Advances | November 27, 2024 | Volume: 9 | Issue: 5 | Pages: 1013-1023

10.1182/bloodadvances.2024014053 | PMID 39602301 Get It

Abstract Progression of disease within 24 months of initial immunochemotherapy (POD24) is a negative prognostic factor for patients with follicular lymphoma (FL). There is no standard treatment after POD24. Assembling an academic-based cohort from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence, we evaluated patterns of care and outcomes for 220 patients with FL with POD24 and retained FL histology. Therapy after POD24 was heterogeneous, with no treatment category accounting for &gt;25% of the total. Among patients initially treated with bendamustine-rituximab, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) was the predominant second-line choice (48%). Among patients initially treated with R-CHOP, aggressive salvage therapy was the predominant second-line choice (38%). Overall response rate to therapy after POD24 was 64% (95% confidence interval [CI], 56-70); complete response rate was 39% (95% CI, 32-46). The median event-free survival for therapy after POD24 was 9.8 months (95% CI, 7.3-12.1); 5-year overall survival (OS) was 71% (95% CI, 65-78). OS was inferior for patients aged &gt;70 years (hazard ratio [HR], 2.31; 95% CI, 1.27-4.20) and those with high-risk FL International Prognostic Index scores at diagnosis (HR, 2.10; 95% CI, 1.23-3.60). No treatment category stood out with more favorable results. Cause of death was predominantly lymphoma related. Patients with follicular histology at their POD24 event had a low cumulative incidence of transformation (1.1% at 5 years). Our study is among the largest cohorts describing contemporary patterns of care for patients with POD24, providing a focused data set useful for interpreting and designing prospective clinical trials in this population.